Award & Investment Overview
LumaWave, a Tulane University spinout developing next-generation fetal monitoring technology, has received a $1.5 million award from the Advanced Research Projects Agency for Health (ARPA-H) to advance a platform capable of directly measuring fetal tissue oxygenation during pregnancy and labor.
The award was made through ARPA-H’s Making Obstetrics Care Smart (MOCS) program, a national initiative focused on modernizing labor and delivery through real-time physiological monitoring.
Founded by Tulane researchers Carolyn Bayer and Vinoin Devpaul Vincely, LumaWave is commercializing a spectral photoacoustic imaging platform developed at Tulane University. The award represents a significant commercialization milestone, building on years of translational research, proof-of-concept funding, customer discovery, intellectual property development, and venture creation supported by the Tulane Innovation Institute.
Approach & Ecosystem Context
LumaWave illustrates how a coordinated university commercialization ecosystem can accelerate the translation of academic research into a venture-backed medical technology company.
The technology originated in Carolyn Bayer’s laboratory before receiving early commercialization support through Tulane’s Provost’s Proof of Concept Fund, enabling development and testing of an initial prototype. The team subsequently participated in NSF I-Corps to validate clinical needs and refine market opportunities while also engaging extensively with Tulane Innovation Institute programs, including innovation competitions, commercialization fellowships, and entrepreneurial development activities.
The commercialization pathway also included patent protection, an exclusive licensing option from Tulane, startup formation, and continued translational funding before securing federal support through ARPA-H.
From a Mind the GAP perspective, LumaWave demonstrates the cumulative impact of coordinated GAP programming. Rather than relying on a single funding source, the company progressed through proof-of-concept funding, customer discovery, commercialization education, startup formation, licensing, venture development, and federal translational funding. This integrated approach reflects how mature university commercialization ecosystems help reduce technical, clinical, regulatory, and market risk before technologies are positioned for larger non-dilutive awards and future private investment.
Innovation & Technology
LumaWave is developing a spectral photoacoustic imaging platform capable of directly measuring oxygen levels within fetal tissue during pregnancy and labor.
The technology combines pulsed light with ultrasound imaging to generate physiological information that conventional ultrasound systems cannot provide. By measuring tissue oxygenation in real time, clinicians may be able to identify fetal hypoxia earlier and make more informed decisions during labor and delivery.
Unlike MRI-based approaches, the LumaWave platform is designed as a portable, lower-cost solution that can be deployed at the point of care while utilizing conventional ultrasound hardware.
Beyond obstetrics, the platform has the potential to support additional clinical applications where non-invasive physiological imaging could improve diagnosis and patient management.
Potential Market Uses and Applications
LumaWave
Potential Clinical Applications
- Fetal oxygen monitoring during labor and delivery
- High-risk pregnancy management
- Maternal-fetal medicine
- Obstetric clinical decision support
Potential Medical Device Applications
- Spectral photoacoustic imaging systems
- Point-of-care physiological imaging
- Portable diagnostic imaging platforms
- Ultrasound-enabled physiological monitoring
Potential Healthcare Applications
- Hospital labor and delivery units
- Community hospitals
- Rural healthcare
- Global maternal health
Tulane University also continues to expand commercialization support through the Innovation Institute, with LumaWave serving as an example of how proof-of-concept funding, venture development programming, and translational research support can advance university discoveries toward commercial impact.
Related Topics
ARPA-H, Making Obstetrics Care Smart, medical device commercialization, university commercialization, proof-of-concept funding, GAP programs, translational research, women’s health innovation, fetal monitoring, biomedical engineering
About innovosource
innovosource tracks GAP programs, including proof-of-concept programs, startup accelerators, translational research initiatives, university venture funds, and commercialization ecosystems that help move university innovations from research to market.
Our coverage is informed by the Mind the GAP Initiative and the GAP COA consortium activity, providing practical insights into the evolving commercialization landscape.
Learn more: https://www.innovosource.com/mind-the-gap/
